Commission - Moderna agreement on delivery of mutation-adapted vaccines
This is the Commission's second agreement with a production company aimed at improving planning and better coordination
The company and the Commission have reached an agreement with Moderna to adjust the delivery schedule of its coronavirus vaccines to the Member States of the European Union, according to today's announcement.
As Health Commissioner Stella Kyriakidou explained in a statement, this is the Commission's second agreement with a production company aimed at improving planning and better coordination with the current needs of the Member States.
In particular, the agreement provides for the postponement for later this year of the delivery of some of the installments that were to be delivered in the second quarter of 2022.6.2
Also, in the event of approval by the Commission and the European Medicines Agency (EMA) of new versions of the vaccine adapted to variants and mutations, doses scheduled for delivery in April, May and June may be delivered as adjunct doses adapted to the known today variants of the virus.
In this scenario, these boosts will start to be delivered from September onwards during the fall and winter of 2022.
The agreement also provides for the delivery of vaccines adapted to future coronavirus mutations, always subject to their approval by Coreper.